Verastem, INC 10-Q quarterly reports

Verastem, Inc. reports increased revenue from its newly approved cancer drug AVMAPKI FAKZYNJA CO-PACK, but also a significant rise in net loss and ongoing 'going concern' doubts.

Verastem, Inc. reports Q2 2025 financial results, highlighting initial product revenue from its newly approved AVMAPKI FAKZYNJA CO-PACK and progress across its oncology pipeline.

Verastem Oncology announces first quarter 2025 financial results, highlighting the FDA approval and launch of AVMAPKI FAKZYNJA CO-PACK and progress in pipeline programs.

Verastem Oncology completed its rolling NDA submission for the avutometinib and defactinib combination in recurrent KRAS mutant low-grade serous ovarian cancer and is seeking accelerated approval.

Verastem Oncology announced positive second quarter results, highlighted by the initiation of a rolling NDA submission for their avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer.

Verastem Oncology announced its first quarter 2024 financial results and provided updates on its clinical programs, including plans for a rolling NDA submission for avutometinib and defactinib.